| Document |
Document Title |
|
WO/2015/150337A1 |
The present invention relates to new kinase inhibitors, more specifically LIM Kinase inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and Prophylaxis of ...
|
|
WO/2015/150839A1 |
A compound of Formula I: R1 -L1 -C(A)(A') - CH2, - L2-R2 or a pharmaceutically acceptable salt thereof, for use in medicine, for example in the treatment of a disease or condition selected from the group comprising cancer, autistic spect...
|
|
WO/2015/148982A1 |
Disclosed herein are methods and compositions for alleviating side effects of statin administration, such as myopathic or myalgic side effects, short-term memory loss, abnormal liver function, glucose intolerance, hyperglycemia, increase...
|
|
WO/2015/146929A1 |
Provided is a compound, or a salt thereof, that has an excellent PKC inhibitory action, and that is useful as a prophylactic or therapeutic agent for immunological diseases, inflammatory diseases, etc. A compound represented by formula (...
|
|
WO/2015/149005A1 |
Methods and compositions for cell therapy using immune modulating peptides comprising a MANF family protein, or fragment thereof, as an adjuvant to improve replacement cell viability and integration. The methods and compositions can be u...
|
|
WO/2015/135089A1 |
The invention relates to a method for treating a muscular dystrophy disease in a patient, said method including the administering of an effective quantity of a botanical medicine isolated from Andrographis paniculata, in combination with...
|
|
WO/2015/137965A1 |
Liquids, substantially clear liquids and foodstuffs are described that contain free acid HMB. The liquids, substantially clear liquids and foodstuffs are substantially free of crude fat and may contain soluble proteins, carbohydrates, vi...
|
|
WO/2015/137387A1 |
Provided are the following: a muscle enhancing drug containing, as an effective component, an amino acid composition consisting of ornithine or a salt thereof, citrulline or a salt thereof, and arginine or a salt thereof; and a compositi...
|
|
WO/2015/137409A1 |
Provided is a drug that allows highly-efficient skipping of exon 51 in the human dystrophin gene. The present invention provides an antisense oligomer which enables exon 51 exon in the human dystrophin gene to be skipped.
|
|
WO/2015/133627A1 |
The present invention provides an agent to prevent or improve debility, the agent containing as an active ingredient isoleucine and threonine, and an agent to prevent or improve debility, the agent further containing as an active ingredi...
|
|
WO/2015/129821A1 |
The present invention provides a compound that has an autotaxin inhibitory effect and is represented by formula (I) (in the formula, R1, R2, R3, R4a, R4b, R5a, and R5b are as defined in the description.), a medicine that uses said compou...
|
|
WO/2015/123750A1 |
Described is a transdermal ethosome composition for the treatment of pain. The transdermal ethosome composition comprises: an alcohol; a phospholipid; water; and a magnesium salt, a TRPV1 receptor agonist, or both a magnesium salt and a ...
|
|
WO/2015/125138A1 |
The present invention relates to the alleviation of adverse side effects resulting from statin therapy. The present invention further relates to the use of an inhibitor of leukotriene C 4 (LTC4) mediated activity for alleviating at least...
|
|
WO/2015/122067A1 |
Provided are: a citrus seed extract-containing composition with which a novel function of citrus (particularly, a citrus seed extract) can be sufficiently exhibited; a food; a drug; and a method for producing the citrus seed extract-cont...
|
|
WO/2015/119126A1 |
The purpose of the present invention is to provide a novel compound having a selective JAK3-inhibiting effect and excellent oral absorption. Moreover, the purpose of the present invention is to provide a medical drug useful, on the basis...
|
|
WO/2015/119249A1 |
Provided are a novel myogenesis accelerator, amyotrophy suppressor, medicinal composition, and TAZ activator. The myogenesis accelerator, amyotrophy suppressor, medicinal composition, and TAZ activator according to the present invention ...
|
|
WO/2015/118365A1 |
The present invention is directed to compositions and methods for the prevention, inhibition, and/or treatment of progressive fibrosis present in various fibroproliferative disorders. In particular, embodiments of the present invention r...
|
|
WO/2015/111602A1 |
Provided are: a method for producing adult oligodendrocyte-type-2 astrocyte progenitor cells from proliferative oligodendrocyte-type-2 astrocyte progenitor cells; and a pharmaceutical composition having as an effectivecomponent thereof a...
|
|
WO/2015/109935A1 |
The invention generally relates to compounds of formula (I) with neural protective effect, and preparation and uses thereof. The compounds have multiple mechanisms or functions, for example, inhibition of monoamine oxidase and cholineste...
|
|
WO/2015/109666A1 |
Disclosed are an ester group-containing aromatic propionamide compound, and a preparation method therefor and uses thereof, and provides a chemical structure formula of the new ester group-containing aromatic propionamide compound. The c...
|
|
WO/2015/106268A1 |
The present disclosure relates to methods, uses, pharmaceutical compositions and kits comprising a sGC stimulator or a pharmaceutically acceptable salt thereof, alone or in combination with one or more additional therapeutic agents, for ...
|
|
WO/2015/106290A1 |
The present disclosure provides antibodies and antigen-binding fragments capable of penetrating cells via an ENT transporter, such as humanized antibodies. The disclosure also provides conjugates comprising the antibodies or antigen-bind...
|
|
WO/2015/099175A1 |
The purpose of the present invention is to provide an antibody exhibiting antagonistic action against IL-33, in particular, an isolated human anti-IL-33 neutralizing monoclonal antibody or fragment thereof in which the amino acid sequenc...
|
|
WO/2015/098963A1 |
Provided is a method for promoting the expression of calreticulin in at least one type of eukaryotic cell. Also provided is a synthetic peptide that can be used in said method. The method provided by the present invention includes prepar...
|
|
WO/2015/093634A1 |
The present invention relates to a pharmaceutical composition containing an extract of Cichorium intybus as an active ingredient for preventing or treating myoatrophy; a food composition containing an extract of Cichorium intybus for pre...
|
|
WO/2015/090232A1 |
The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also pro...
|
|
WO/2015/089575A1 |
The present invention relates generally to a method of diagnosing and/or monitoring the development or progress of chronic fatigue syndrome. More particularly, the present invention relates to a method of diagnosing and/or monitoring the...
|
|
WO/2015/095713A1 |
The invention provides enantiopure deuterium-enriched bupropion, pharmaceutical compositions, and methods of treating neurological disorders, movement disorders, cardiovascular disorders, metabolic disorders, and other disorders using en...
|
|
WO/2015/094772A1 |
Methods of increasing skeletal muscle protein synthesis in a subject are provided. Methods of increasing or maintaining mammalian target of rapamycin (mTOR) activation are also provided. Such methods include a step of administering at le...
|
|
WO/2015/093901A1 |
The present invention relates to a composition containing TM-53 and TM-54 as an active ingredient for inducing or promoting myocyte differentiation, a pharmaceutical composition for muscle regeneration, and a pharmaceutical composition f...
|
|
WO/2014/117155A9 |
The present invention provides, among other things, methods and compositions for treating muscular dystrophy, in particular, Duchenne muscular dystrophy (DMD). In some embodiments, a method according to the present invention includes adm...
|
|
WO/2015/089452A1 |
The invention relates to the use of an animal-protein-free botulinum toxin composition to treat a disease, disorder or condition in a patient in need thereof whereby the animal-protein-free botulinum toxin composition exhibits a longer l...
|
|
WO/2015/085118A1 |
The present invention is directed to a method of treating spasticity in a human subject, comprising administering intrathecally to the subject a therapeutically effective amount of dantrolene or a pharmaceutically acceptable salt thereof...
|
|
WO/2015/082938A1 |
The present invention relates to a compound of formula I, or a pharmaceutically acceptable salt thereof : (I) wherein: n is 0 or 1; R1 is selected from H, alkyl and aralkyl, wherein said alkyl and aralkyl groups may be optionally substit...
|
|
WO/2015/078935A1 |
The application relates to means, which derive from TAL effectors and TALENs. The structure of the means of the application is especially adapted for partial or full deletion of at least one DNA tandem repeat, more particularly for parti...
|
|
WO/2015/077353A1 |
Methods of suppressing cachexia in a mammal with cancer comprising administering HDAC inhibitors are provided. Aspects include methods of administering an HDAC class 1 and 2b inhibitor in an amount effective to substantially maintain the...
|
|
WO/2015/069669A1 |
Nanostructure conjugates, methods for their preparation, and methods for their use are described. The nanostructure conjugates are useful in inhibiting, activating, and modulating extrasynaptic receptors and ion channels, and in treating...
|
|
WO/2015/070158A1 |
The present invention provides methods comprising the in vivo delivery of small nucleic acid molecules capable of mediating RNA interference and reducing the expression of myostatin, wherein the small nucleic acid molecules are introduce...
|
|
WO/2015/069115A1 |
The invention related to methods of treatment of an individual suffering from or at risk of suffering from a selective estrogen-receptor modulator (SERM) induced adverse drug reaction. The invention additionally relates to a pharmaceutic...
|
|
WO/2015/064585A1 |
The purpose of the present invention is to provide a pharmaceutical composition or method which is widely applicable to myopathies accompanying a decrease in muscle strength and can increase muscle strength or delay the progression of a ...
|
|
WO/2015/061779A1 |
Methods for treating a subject in need thereof are provided which include administering a pharmaceutical composition comprising a protein transduction reagent-modified reprogramming protein to the subject, wherein the protein transductio...
|
|
WO/2015/060430A1 |
The purpose of the present invention is to provide a method for screening substances that participate in metabolic conversion and a kit for screening substances that participate in metabolic conversion. Said problem can be solved with mu...
|
|
WO/2015/060650A2 |
The present invention relates to a composition for preventing or treating amyotrophic lateral sclerosis, the composition containing, as an active ingredient, two or more isoforms of a hepatocyte growth factor (HGF) or a polynucleotide en...
|
|
WO/2015/056713A1 |
The problem of the present invention is to provide a peptide that functions as a c-Met agonist. The present invention provides a peptide complex formed from two or more peptides that couple with a c-Met protein and a linker that joins th...
|
|
WO/2015/058161A1 |
Studies of the pathogenic mechanisms underlying human myopathies and muscular dystrophies often require animal models, but models of some human diseases are not yet available. The present invention provides methods to promote the engraft...
|
|
WO/2015/050160A1 |
The present invention provides an anti-aging pharmaceutical composition for muscle containing as the active ingredient parathyroid hormone, a parathyroid hormone derivative, or a salt thereof. Preferably the parathyroid hormone derivativ...
|
|
WO/2015/051283A1 |
Methods for modulating expression of SMN1 and/or SMN2 in cells obtained from subjects having ALS or in subjects having ALS using single stranded oligonucleotides are provided. Methods for treating ALS using single stranded oligonucleotid...
|
|
WO/2015/049630A1 |
This relates to the use of an IGF-1 mimetic in human therapy. In particular, disclosed herein is the use of an IGF-1 precursor protein, particularly a human IGF-1 precursor protein, comprising the E-peptide for the treatment of Spinal an...
|
|
WO/2015/042685A1 |
Compounds which inhibit the formation and/or accumulation of RNA foci, such as those due to polynucleotide repeats (e.g., trinucleotide repeats) are described herein. Also described herein are uses of such compounds, such as for the inhi...
|
|
WO/2015/037656A1 |
Autophagy-regulating miRNA molecules according to the present invention are formed from base sequences represented by any of SEQ ID NO: 1-203 in the sequence listing. These miRNA molecules were identified using an miRNA screening method ...
|
